NASDAQ
84.00USD
+3.39 (+4.21%)
We have scored 20 news catalysts on Celcuity Inc. (CELC) over the past 12 months. The biggest single-day move next to one of them came Jul 15, 2026, when CELC closed −17.6%: “Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer”. Coverage across the window leans positive (average ticker sentiment +0.36). Most of the impact sits in forward growth expectations and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.1B
P/E
—
EPS
—
Beta
0.16
52W range
44.42-151.02
Day range
82.06–84.35
Open
82.41
Prev close
80.61
Volume
718.1K
Avg volume
1.3M
Dividend
0.00
IPO
2017-09-19
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Celcuity Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Celcuity Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for CELC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
